This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a leading provider of clinical development technology, today announced 80% revenue growth in 2024 across enterprise customers adopting a SaaS model for portfolio-level electronic clinical outcomes assessment (eCOA) technology investments compared to study-by-study contracts. 5000 in 2024.
This transformation will particularly benefit organizations that can effectively combine AI expertise with traditional pharmaceutical knowledge, creating new competitive advantages in drugdevelopment efficiency, cost management, and market responsiveness.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drugdevelopment and diagnostics. Originally announced October 29th, 2024 More information at aignostics.com.
By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drugdevelopment. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Originally announced January 8th, 2024 Petra Jantzer, Ph.D.,
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. There is a growing interest in the integration of safety services with technology, and this will continue into 2024. In fact, we got so many that we had to narrow them down to just the best and most interesting.
AI-powered* platform takes eCOA off the critical path to study startup for lifesciences industry PALO ALTO, Calif.–(BUSINESS In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.” –(BUSINESS WIRE)– Medable Inc. ,
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. 2024 will likely see continued hype regarding A.I. True advancements will be seen in predictive algorithms for drug benefits and toxicities, particularly in cancer treatment. in medicine in all aspects.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content